Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Brenda Bartman on Jun 7th, 2026

Coya Therapeutics, Inc. (NASDAQ:COYA – Get Free Report) has received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $15.3333.

Several equities research analysts have weighed in on COYA shares. Chardan Capital restated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Monday, March 16th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Monday, March 23rd. D. Boral Capital restated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a report on Friday, April 10th. Roth Mkm started coverage on Coya Therapeutics in a report on Friday. They set a “buy” rating and a $12.00 price target on the stock. Finally, Wall Street Zen downgraded Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th.

View Our Latest Analysis on Coya Therapeutics

Coya Therapeutics Stock Down 9.2%

NASDAQ:COYA opened at $4.42 on Friday. Coya Therapeutics has a 52 week low of $3.71 and a 52 week high of $7.75. The company has a market capitalization of $103.69 million, a P/E ratio of -3.84 and a beta of 0.62. The stock’s fifty day moving average is $4.45 and its two-hundred day moving average is $4.90.

Coya Therapeutics (NASDAQ:COYA – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. The firm had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.15 million. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%. Sell-side analysts anticipate that Coya Therapeutics will post -1.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Occudo Quantitative Strategies LP acquired a new position in shares of Coya Therapeutics during the 4th quarter worth about $66,000. CIBC Private Wealth Group LLC acquired a new position in shares of Coya Therapeutics during the 4th quarter worth about $47,000. JPMorgan Chase & Co. acquired a new position in Coya Therapeutics in the third quarter valued at approximately $28,000. Cetera Investment Advisers boosted its holdings in Coya Therapeutics by 36.4% in the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after purchasing an additional 8,000 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Coya Therapeutics by 55.4% in the first quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock valued at $410,000 after purchasing an additional 37,064 shares in the last quarter. 39.75% of the stock is owned by institutional investors and hedge funds.

About Coya Therapeutics

(Get Free Report)

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.